Glycemic control, therapy trends, and diabetes complications were evaluated in LANDMARC, a prospective observational 3-year study (CTRI/2017/05/008452), having participants with T2D on ≥2 antihyperglycemic medications. This subgroup analysis of 114 sites in North India (Delhi, Jaipur, Lucknow) included 1686 participants (mean [SD] baseline [BL] age: 51.7 [8.8] years, T2D duration: 8.7 [5.5] years and A1C: 8.1% [1.6]). At BL, most were insulin-naïve (n=1332; 79.0%), relying mainly on OADs (n=1324; 78.5%). At 3 years, 1028 (70.1%) participants were on OADs only, while 414 (28.2%) were on insulin + OADs. Biguanides was the most prescribed drug class (BL: 1558 [92.4%] and 3-years: 1313 [89.5%]). Basal insulin usage increased from BL (n=199; 11.8%) to 3 years (n=284; 19.4%). At 3 years, there was a decrease in the mean (SD) A1C by 0.8 (1.7) %, FPG by 17.0 (51.4) mg/dL, and PPG by 19.1 (79.0) mg/dL; and an increase in proportion of those with A1C<7% (BL: 257 [21.2%]; 3 years: 363 [38.6%]). Peripheral vascular disease and neuropathy were most common macrovascular and microvascular complications, respectively (Table). Hypertension and dyslipidemia were the most common CV risk factors reported at 3 years. The highest burden of hypertension was noted in North India. This pivotal understanding of regional trends in glycemia, therapy, and complications may help strategize future diabetes management practices in India.
A. Mithal: Other Relationship; Sanofi. S. Wangnoo: None. A.H. Zargar: None. R. Chawla: None. M. Gupta: None. V. Mittal: None. D. Khandelwal: None. S. Julka: Other Relationship; Sanofi, Eli Lilly and Company, Novo Nordisk, USV Private Limited. S. Jindal: None. S. Lodha: None. S.S. Banzal: None. S.K. Menon: Employee; Sanofi. A. Gadekar: None. D. Chodankar: Employee; Sanofi.
Sanofi
